Work to lower drug costs and prevent price gouging.

Val T. Hoyle · Oregon · Democratic

policy impact 77.00 specificity 73.00 extraction confidence 9700%

Commitment kind: unknown. Promised action: not established. Promised outcome: not established. Deadline: unknown; not assumed expired.

Occurrences

Standing up to big pharma to bring down drug costs, and going after anyone who tries to price gouge Oregonians.

Commits to reducing prescription drug costs and targeting price gouging.

Priorities | Val Hoyle for Congress
campaign · campaign_site · model gpt-5.4-mini

In Congress, she will continue to work with anyone regardless of party to pass common sense ways to bring prices down and wages up, including standing up to big pharma to bring down drug costs, and going after anyone who tries to price gouge Oregonians.

Commitment to lower drug costs and oppose price gouging.

Priorities | Val Hoyle for Congress
campaign · other · model gpt-5.4-mini

To require persons who undertake federally funded research and development of a biomedical product or service to enter into reasonable pricing agreements with the Secretary of Health and Human Services, and for other purposes.

Hoyle introduced H.R. 10094 to require reasonable pricing agreements for federally funded biomedical products and services, aligning with a commitment to lower prescription drug costs and prevent price gouging.

H.R. 10094 (IH) - Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026 - BILLS-119hr10094ih | Content Details | GovInfo
primary · other · model gpt-5.5

Evidence

unverified · Source version 15927 · locator unknown

"We need to lower the cost of prescription drugs, hold big corporations accountable for price-gouging..." The page also says Hoyle introduced the Affordable Pricing for Taxpayer-Funded Prescription Drugs Act, which "would lower prescription drug prices by preventing pharmaceutical companies from price-gouging Americans on drugs that are developed with taxpayer money."

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Official issue-page language shows Hoyle still publicly identifies lowering prescription drug costs and preventing price gouging as an active priority in her current office, but it does not show new legislative or administrative success during the lookback window.

unresolved same_term

Health | Congresswoman Val Hoyle
secondary · model gpt-5.4-mini · confidence 84%

unverified · Source version 9975 · locator unknown

Hoyle announced legislation to combat price gouging on taxpayer-funded prescription drugs, saying the bill would require affordable pricing agreements before granting exclusive rights to develop prescription drugs or other healthcare products.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): This is the clearest official evidence of concrete action behind the promise: Hoyle introduced a bill targeting prescription drug price gouging. But the bill page shows only introduction and referral, not enactment or later legislative progress.

partial same_term A for effort

Representatives Hoyle and Doggett Introduce Legislation to Lower Prescription Drug Pricing | Congresswoman Val Hoyle
secondary · model gpt-5.4-mini · confidence 91%

unverified · Source version 58403 · locator unknown

Newest: Rosa L. DeLauro (D-CT), Sep 1, 2026

Unverified model/legacy excerpt; not proof. AI summary (separate from source): During the lookback window, the reintroduced drug-pricing bill gained additional support, with the newest listed cosponsor joining on September 1, 2026. This is continued effort, not enacted delivery.

unresolved later_term A for effort

H.R. 10094: Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026 | Docket
secondary · model gpt-5.5 · confidence 76%

verified · Source version 49987 · locator 1332

Ms. Hoyle of Oregon (for herself, Mr. Doggett, Ms. Stansbury, Mr. Takano, Ms. Norton, Ms. Tlaib, Ms. Jayapal, and Mr. Casar) introduced the following bill; which was referred to the Committee on Energy and Commerce

Fetched verbatim passage. AI summary (separate from source): GovInfo confirms Hoyle reintroduced the Affordable Pricing for Taxpayer-Funded Prescription Drugs Act in the 119th Congress and that the official action was referral to committee.

unresolved later_term A for effort

H.R. 10094 (IH) - Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026 - BILLS-119hr10094ih | Content Details | GovInfo
primary · model gpt-5.5 · confidence 93%

verified · Source version 58405 · locator 1970

any reasonable pricing formula shall ensure, without prejudice to any other standards or negotiated provisions for reasonable pricing, that residents of the United States are not charged more for the biomedical product or service involved than the reference price for countries with large economies and high incomes.

Fetched verbatim passage. AI summary (separate from source): The official bill text targets the promise substance by requiring reasonable pricing for taxpayer-funded biomedical products and limiting U.S. prices against international reference prices.

unresolved later_term A for effort

H.R. 10094 Introduced in House Text
secondary · model gpt-5.5 · confidence 92%

verified · Source version 58406 · locator 1865

Representatives Val Hoyle (OR-04) and Lloyd Doggett (TX-37) reintroduced the Affordable Pricing for Taxpayer-Funded Prescription Drugs Act to lower the cost of prescription drugs for Americans.

Fetched verbatim passage. AI summary (separate from source): Hoyle's office describes the 2026 reintroduction as aimed at lowering prescription drug costs, showing renewed effort shortly before the lookback window.

unresolved later_term A for effort

REPS. HOYLE AND DOGGETT REINTRODUCE LEGISLATION TO LOWER PRESCRIPTION DRUG PRICING | Congresswoman Val Hoyle
primary · model gpt-5.5 · confidence 88%

unverified · Source version 58407 · locator unknown

Latest Action: House - 05/12/2023 Referred to the Subcommittee on Health. This bill has the status Introduced

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Congress.gov shows Hoyle's original 118th Congress bill remained introduced and referred to subcommittee; because the 118th Congress ended without enactment, this same-term effort did not deliver the promised policy outcome.

never same_term A for effort

H.R.3093 - 118th Congress (2023-2024): Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2023 | Congress.gov | Library of Congress
secondary · model gpt-5.5 · confidence 91%

Assessments

Public state: pending As of 2026-09-18 · verified · . Original AI recommendation (not independently established): unresolved. later_term A for effort

The verified commitment is to require reasonable-pricing agreements for federally funded biomedical R&D. Verified evidence shows Hoyle materially advanced that policy by introducing/reintroducing H.R. 10094, and the bill text contains the reasonable-pricing mechanism. But the verified passages show introduction and committee referral, not enactment or an achieved reduction in drug costs/price gouging. With no enacted outcome and no expired deadline as of 2026-09-18, this remains unresolved rather than delivered or partial.

provider codex_cli · model gpt-5.5 · confidence 92%

Public state: unverified As of unknown · legacy_unverified · . Original AI recommendation (not independently established): never. same_term A for effort

Hoyle made a concrete same-term legislative effort by introducing H.R. 3093, the Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2023, aimed at lowering prescription drug prices and preventing price gouging for taxpayer-funded drugs. However, the bill remained at the introduction/referral stage in the 118th Congress and did not become law, and the evidence does not show another enacted federal outcome attributable to Hoyle that delivered the promised result. Because there was a serious legislative attempt but no fulfilled policy outcome, this should be scored as not delivered with an effort badge.

provider codex_cli · model gpt-5.5 · confidence 90%